EVLO Key Statistics, Chart & Performance
The current stock price of EVLO is 0.3165 USD. In the past month the price increased by 3.84%. In the past year, price decreased by -99.13%.
EVLO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EVLO. When comparing the yearly performance of all stocks, EVLO is a bad performer in the overall market: 99.86% of all stocks are doing better.
EVLO Financial Highlights
Over the last trailing twelve months EVLO reported a non-GAAP Earnings per Share(EPS) of -29. The EPS decreased by -131.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -399.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EVLO Forecast & Estimates
7 analysts have analysed EVLO and the average price target is 10.2 USD. This implies a price increase of 3122.75% is expected in the next year compared to the current price of 0.3165.
EVLO Ownership
EVLO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.46 | 394.585B | ||
| AMGN | AMGEN INC | 16.24 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 16.67 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.91 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.35 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.17 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.52 | 28.432B | ||
| INCY | INCYTE CORP | 12.49 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVLO
Company Profile
Evelo Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Foxboro, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2018-05-09. Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The firm is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. The company has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.
Company Info
EVELO BIOSCIENCES INC
124 Washington Street, Suite 101
FOXBORO MASSACHUSETTS 02139 US
CEO: Balkrishan Simba Gill
Employees: 66
Phone: 16175770300
EVELO BIOSCIENCES INC / EVLO FAQ
What does EVLO do?
Evelo Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Foxboro, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2018-05-09. Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The firm is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. The company has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.
What is the stock price of EVELO BIOSCIENCES INC today?
The current stock price of EVLO is 0.3165 USD. The price decreased by -14.46% in the last trading session.
What is the dividend status of EVELO BIOSCIENCES INC?
EVLO does not pay a dividend.
What is the ChartMill rating of EVELO BIOSCIENCES INC stock?
EVLO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Who owns EVELO BIOSCIENCES INC?
You can find the ownership structure of EVELO BIOSCIENCES INC (EVLO) on the Ownership tab.